1. Home
  2. RCEL vs BIOA Comparison

RCEL vs BIOA Comparison

Compare RCEL & BIOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Avita Medical Inc.

RCEL

Avita Medical Inc.

HOLD

Current Price

$3.52

Market Cap

114.3M

Sector

Health Care

ML Signal

HOLD

Logo BioAge Labs Inc.

BIOA

BioAge Labs Inc.

HOLD

Current Price

$12.97

Market Cap

175.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RCEL
BIOA
Founded
N/A
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
114.3M
175.7M
IPO Year
N/A
2024

Fundamental Metrics

Financial Performance
Metric
RCEL
BIOA
Price
$3.52
$12.97
Analyst Decision
Buy
Buy
Analyst Count
5
4
Target Price
$11.75
$11.33
AVG Volume (30 Days)
201.4K
403.7K
Earning Date
11-06-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$72,401,000.00
$5,917,000.00
Revenue This Year
$13.12
N/A
Revenue Next Year
$27.56
N/A
P/E Ratio
N/A
N/A
Revenue Growth
20.59
N/A
52 Week Low
$3.33
$2.88
52 Week High
$14.16
$13.10

Technical Indicators

Market Signals
Indicator
RCEL
BIOA
Relative Strength Index (RSI) 37.63 83.65
Support Level $3.33 $12.00
Resistance Level $3.58 $13.10
Average True Range (ATR) 0.18 0.72
MACD 0.01 0.32
Stochastic Oscillator 22.31 97.20

Price Performance

Historical Comparison
RCEL
BIOA

About RCEL Avita Medical Inc.

Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in rollout across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.

About BIOA BioAge Labs Inc.

Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others.

Share on Social Networks: